STOCK TITAN

Bowman Consulting Group Ltd. 10-Q Filings

BWMN NASDAQ

Every 10-Q that Bowman Consulting Group Ltd. (BWMN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 10-Q covers the quarterly report filed between annual reports, so if you follow BWMN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BWMN filings page.

Rhea-AI Summary

Bowman Consulting Group Ltd. reported higher revenue but weaker profitability for the quarter and first half of 2026. For the three months ended June 30, 2026, gross contract revenue rose to $146.1 million from $122.1 million a year earlier, with net income of $2.5 million versus $6.0 million in 2025 as operating expenses and interest costs increased. For the six-month period, revenue grew to $272.6 million from $235.0 million, but the company posted a net loss of $1.2 million compared with net income of $4.3 million in the prior-year period.

Operating cash flow declined to $3.7 million from $16.3 million, while borrowings under the revolving credit facility increased to $136.2 million from $95.4 million, contributing to higher interest expense. Total assets were $620.1 million and shareholders’ equity $256.5 million at June 30, 2026. Bowman continued its acquisition strategy, completing one small acquisition and recognizing additional goodwill and intangibles, and it had approximately $440.2 million in remaining performance obligations, mostly expected to convert to revenue within two years. The company also repurchased common stock under a $25 million authorization, buying 381,936 shares for $12.2 million year-to-date, and later entered into a definitive all-cash merger agreement with affiliates of Bernhard Capital Partners.

Rhea-AI Summary

Bowman Consulting Group Ltd. reported higher revenue but a larger loss for the quarter ended March 31, 2026. Gross contract revenue rose to $126.5 million from $112.9 million, a 12% increase, driven mainly by fixed-fee work.

Net loss widened to $3.7 million from $1.7 million, though Adjusted EBITDA improved to $16.8 million from $14.5 million. Operating cash flow was strong at $11.6 million. Bowman expanded its revolving credit facility capacity to $250.0 million, with $108.8 million outstanding, and ended the quarter with $12.0 million in cash.

The company continued its acquisition strategy and recorded goodwill of $173.6 million and intangible assets of $85.6 million. It repurchased 288,098 shares for $9.2 million under its 2025 authorization, leaving $6.4 million available. Backlog totaled about $524.1 million, with roughly 80% expected to convert to revenue within twelve months.

Rhea-AI Summary

Bowman Consulting Group (BWMN) reported stronger Q3 results. Gross contract revenue rose to $126.0 million from $113.9 million, with nine‑month revenue at $361.1 million versus $313.3 million. Operating income improved to $5.3 million, driving net income of $6.6 million and diluted EPS of $0.37 for the quarter. For the nine months, net income reached $10.9 million with diluted EPS of $0.62, a clear turnaround from last year’s loss.

Cash from operations was $26.5 million year‑to‑date, lifting cash to $16.2 million. The revolving credit facility balance increased to $57.0 million; capacity was expanded to $140.0 million in March 2025. Contract mix remained largely fixed‑fee, and remaining performance obligations were $334.0 million, with 89.1% expected within 12 months. Bowman completed three small acquisitions in 2025 (total consideration $6.6 million), while 2024’s Surdex deal added scale but posted a small pre‑tax loss year‑to‑date.

Shareholder returns continued: the 2024 repurchase plan bought 1,368,576 shares at an average $23.97; a new $25 million authorization began June 2025 with no repurchases yet. Shares outstanding were 17,373,129 as of November 1, 2025. Taxes were a key swing factor, with a negative effective rate for the nine months due to discrete items and changes related to R&D expensing.